 |
Complications in Oncology Practice: Venous Thromboembolism and Tumor Lysis Syndrome CME Author Information and Disclosures Release Date: August 18, 2008; Valid for credit through August 18, 2009 | Physicians - maximum of 1.5 AMA PRA Category 1 Credit(s)™ for physicians | | To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Medscape. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Describe the risk factors that cancer patients face for the development of VTE and understand the treatment guidelines for the prevention and treatment of VTE in cancer patients who are hospitalized, ambulatory, or undergoing surgery
- Discuss
options for prophylaxis and treatment of VTE in cancer patients and describe the relative contraindications and risks associated with anticoagulation therapy in cancer patients
- Describe the risk factors for developing TLS and discuss strategies utilized in the prevention and treatment of TLS
- Examine the safety and efficacy of different treatment modalities for lowering uric acid in TLS
Authors and
Disclosures Mohammad Jahanzeb, MD, FACP
Disclosure: Mohammad Jahanzeb, MD, FACP, has disclosed that he has received research grants from Genentech, Pfizer, Merck, and Exagen. Dr. Jahanzeb has also disclosed that he has served on the speaker’s bureau for Genentech, sanofi-aventis, Roche, GlaxoSmithKline, Abraxis, and AstraZeneca and has served on the advisory board for
Genentech, Eli Lilly, Easi, AstraZeneca, Novartis, Pfizer, GlaxoSmithKline, Abraxis, and sanofi-aventis. David J. Straus, MD
Disclosure: David J Straus, MD, has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of products and devices to be discussed in his presentation or who may financially support the educational activity. He has received payment for his role on
advisory boards for Amgen Inc, Eisai Inc, and Therakos, Inc. He has also received payment for his role as a consultant for a data review committee for Ligand Pharmaceuticals. Ammar Hasan
Disclosure: Ammar Hasan, PharmD, has disclosed no relevant financial relationships. Jill Chamberlain
Disclosure: Jill W. Chamberlain has disclosed no
relevant financial relationships. Margie Miller
Disclosure: Margie Miller has disclosed no relevant financial relationships. |
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
